Warning: session_start() [function.session-start]: open(/var/lib/php/session/sess_1ahm4tt2b1qcl10lm99pkao323, O_RDWR) failed: Permission denied (13) in /var/www/html/realclearpolitics.com/httpdocs/congressional_bill_tracker/app/application/mvc.php on line 3

Warning: file_get_contents(http://congress.api.sunlightfoundation.com/bills?apikey=f323a285321542e3925601990ef5c589&congress=114&bill_type=hr&number=931&fields=versions,latest_version) [function.file-get-contents]: failed to open stream: HTTP request failed! HTTP/1.1 504 Gateway Time-out in /var/www/html/realclearpolitics.com/httpdocs/congressional_bill_tracker/app/application/model.php on line 738
RCP Congressional Bill Tracker - H.R. 931


Track Members of Congress & Get Email Updates on Their Activity

H.R. 931: HEAL Act

Title: HEAL Act

Introduced: Feb 12, 2015 (114th Congress)

Sponsor: Rep. Rosa L. DeLauro [D-CT3]

Status: Referred to Committee - Referred to the House Committee on Energy and Commerce.

Summary: Helping Effective Antibiotics Last Act of 2015 or the HEAL Act This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA) to approve an antibacterial drug or biological product that is intended to treat a serious or life-threatening condition only for treating a well-defined population of patients. To be approved, the antibacterial product must produce superior outcomes over available therapies in the well-defined patient population. A product approved by this pathway must include in its prescribing information the population of patients expected to benefit from using the product and the method for identifying members of that population. The FDA must require each product to have a risk evaluation and mitigation strategy. The Centers for Disease Control and Prevention must monitor changes to bacterial drug resistance and changes to patient outcomes caused by bacterial drug resistance. Upon approval of antibacterial products, the FDA must identify susceptibility test interpretive criteria (the drug concentrations where a type of bacteria is categorized as susceptible, intermediate, or resistant) and update the criteria as needed based upon evidence of changes in patient outcomes. To be eligible for an exclusivity period extension, a qualified infectious disease product must be demonstrated to produce superior outcomes over available therapies. The FDA must issue guidance on the development of target product profiles for antibacterial drugs.


Warning: Unknown: open(/var/lib/php/session/sess_1ahm4tt2b1qcl10lm99pkao323, O_RDWR) failed: Permission denied (13) in Unknown on line 0

Warning: Unknown: Failed to write session data (files). Please verify that the current setting of session.save_path is correct (/var/lib/php/session) in Unknown on line 0